FDA Approves ATS Medical’s 3f Aortic Biprosthesis, 3f Enable Still in the Works

The FDA has approved ATS Medical’s 3f Aortic Bioprosthesis (3fAB), a poorly named, but potentially revolutionary pericardial aortic tissue valve. 3fAB’s blood flow dynamics and improved stress distribution mimic the functional characteristics of the native valve, offering patients a more durable aortic...

Clarient: Q3 Revenues up 59%; Raises Guidance

Third quarter revenues at Clarient increased 59% to $19.0 million from the $11.9 million reported in Q3 2007. This marks the company’s 17th consecutive quarter of sequential revenue growth. Higher testing volume, a favorable service mix and higher Medicare reimbursement rates drove revenues. Testing volume...

[Video Profile] Sherlock-NMD

When an athlete is injured, their career and value to the team are at risk. At all levels of athletics, including everyday fitness enthusiasts, the frequency and severity of injuries makes it imperative to find better methods to identify and treat biomechanical muscular skeletal dysfunctions. Currently, the...

Cynosure: Profitable, Growing and Flush with Cash, but Investors Don’t Care

Quarterly revenues at Cynosure, a developer of laser-based aesthetic systems, grew 21% year-over-year, from $31.5 million in Q3 2007 to $38.2 million in the most recent quarter. Second quarter revenues were $39.2 million. Net income for the third quarter of 2008 was $3.2 million compared with net income of...

Langer Sheds Orthotics Business to Cut the Fat

Only months after Langer sold its Bi-Op subsidiary for less than its purchase price, the company announced the sale of its custom orthotics business to The Orthotic Group (TOG), a manufacturer of prescription custom foot orthotics, orthotic footwear and gait analysis equipment. TOG paid approximately $4.7...

Nothing But Sunshine and Roses for Endologix, Save its Share Price

Endologix, developer of a treatment for abdominal aortic aneurysms (AAA), saw revenues increase 42% in its third quarter. The company reported $9.4 million in sales and expects “at least” $10 million in fourth quarter revenue. If all goes to plan, Endologix is on track for full-year sales growth of 38%...

Candela Explores Strategic Alternatives in Challenging Aesthetics Market

First Quarter Results: Revenues at Candela Corporation, a maker of aesthetic lasers, decreased 24 percent year-over-year, to $26.9 million in the most recent quarter from $35.5 million last year. The decrease in revenues took its toll on the bottom line: the company reported a net loss of $4.0 million. In...

MDMA